Opendata, web and dolomites

Wirecath SIGNED

Novel Catheter for the Diagnosis of Cardiovascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Wirecath project word cloud

Explore the words cloud of the Wirecath project. It provides you a very rough idea of what is the project "Wirecath" about.

cardiovascular    commercialise    position    assessing    opportunity    lasting    place    disease    sme    optimises    instrument    bases    group    reduce    manoeuvrability    prevention    launch    2019    tools    benefits    burden    shareholders    device    evaluation    budgets    deaths    artery    providers    cad    error    superior    first    considerable    plan    coronary    pressure    resistance    angina    arteries    solutions    leads    accuracy    grants    heart    clinical    severe    intends    government    million    follow    shortness    complications    standard    myocardial    trust    effectiveness    strategic    premium    technologies    plans    obstructive    death    narrowings    applicable    diagnosis    diagnostic    severity    clinically    treatment    perform    attack    cavis    healthcare    misdiagnosis    innovation    cardiologists    wires    medical    wirecath    man    competing    commercial    offers    hydrostatic    sensor    patient    patients    liable    investment    good    progression    substantially    validate    diseases    breath   

Project "Wirecath" data sheet

The following table provides information about the project.

Coordinator
CAVIS TECHNOLOGIES AB 

Organization address
address: KUNGSANGSVAGEN 29A 3TR
city: UPPSALA
postcode: 753 23
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CAVIS TECHNOLOGIES AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack. Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers. The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today. With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value. With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WIRECATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WIRECATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More